(Q34614260)

3 August 2017

1 reference

title

DNA vaccines for biodefense (English)

1 reference

3 August 2017

2

Connie S Schmaljohn

1 reference

3 August 2017

1

Lesley C Dupuy

1 reference

3 August 2017

1 December 2009

1 reference

Expert Review of Vaccines

3 August 2017

1 reference

3 August 2017

8

1 reference

3 August 2017

12

1 reference

3 August 2017

1739-1754

1 reference

Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases

3 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Electroporation-based DNA immunisation: translation to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

In vitro correlate of immunity in a rabbit model of inhalational anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Systemic and mucosal antibody responses following retroductal gene transfer to the salivary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Potentiation of an anthrax DNA vaccine with electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Adenovirus-based prime-boost immunization for rapid vaccination against anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Isolation of genetically diverse Marburg viruses from Egyptian fruit bats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Status and challenges of filovirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Processing of the Ebola virus glycoprotein by the proprotein convertase furin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Development and characterization of a mouse model for Marburg hemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Immunization for Ebola virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Development of a preventive vaccine for Ebola virus infection in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Vaccine To Confer to Nonhuman Primates Complete Protection against Multistrain Ebola and Marburg Virus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Marburg virus vaccines: comparing classical and new approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Neutralizing and protective antibodies directed against vaccinia virus envelope antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan Equine Encephalitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Efficacy of DNA vaccination against western equine encephalitis virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

A DNA prime, orally delivered protein boost vaccination strategy against viral encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Presentation of protective antigen to the mouse immune system: immune sequelae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Genetic immunization against anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.132

21 January 2018

Identifiers

DOI

10.1586/ERV.09.132

1 reference

3 August 2017

1 reference

PubMed ID

19943766